Q1 Earnings Forecast for XOMA Issued By Leerink Partnrs

XOMA Co. (NASDAQ:XOMA) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of XOMA in a report issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings of ($0.31) per share for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

XOMA (NASDAQ:XOMA) last issued its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million.

A number of other research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $104.00 price target on shares of XOMA in a research note on Wednesday. StockNews.com downgraded shares of XOMA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th.

XOMA Price Performance

Shares of XOMA opened at $21.06 on Wednesday. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00. The stock has a market cap of $248.15 million, a PE ratio of -6.05 and a beta of 1.00. The firm has a 50-day simple moving average of $24.45 and a two-hundred day simple moving average of $27.20. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Woodline Partners LP lifted its holdings in shares of XOMA by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock valued at $4,107,000 after buying an additional 60,927 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares during the period. Barclays PLC increased its position in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the period. Los Angeles Capital Management LLC acquired a new stake in XOMA in the 4th quarter valued at $206,000. Finally, Renaissance Technologies LLC boosted its stake in XOMA by 89.8% in the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 7,619 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.20% of the stock is owned by insiders.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.